文献速递慢性肾脏病急性肾损伤

寻求平衡:探索慢性肾脏病患者急性冠脉综合征管理中出血与缺血风险之间的细红线

The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients.
PubMed 文献 · Nephrol Dial Transplant · 2017-01-01

综述指出慢性肾脏病(CKD)患者急性冠脉综合征(ACS)的出血与血栓风险均高,但在大型随机对照试验(RCT)中代表性不足,缺乏特异性推荐证据。CKD合并ACS患者诊断更晚、急性干预更少、药物过量及介入治疗不足风险更高。作者呼吁开发更清晰决策算法并强调依据实时肾功能调整药物剂量,未来指南应细化CKD合并ACS的评估。

要点

  • CKD合并ACS患者出血与血栓风险均高,但大型RCT代表性不足,缺乏特异性推荐证据。
  • CKD合并ACS患者诊断更晚、接受急性干预更少,药物过量及介入治疗不足风险更高。
  • 未来指南应细化CKD合并ACS评估,并强调依据实时肾功能调整药物剂量。

核心结论

  • 缺乏RCT不应妨碍依赖临床常识,开发更清晰且结局更好的决策算法是迫切优先事项。
  • 未来指南应进一步细化CKD合并ACS的评估,并更加强调依据实时肾功能正确调整药物剂量。
  • 在制定出具体措施并转化为实际降低出血风险的策略之前,提供者将被迫在一条尚未明确建立的细红线上平衡。

研究设计与样本

  • 本文为综述,检索范围未在摘要中报告。

主要发现

  • CKD患者冠状动脉疾病和ACS均常见,且出血和血栓风险均较高。
  • CKD合并ACS患者较无ACS的CKD患者诊断更晚、接受的急性干预更少,且药物过量及介入治疗处方不足/执行不足的风险更高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • CKD患者在大型RCT中代表性不足,缺乏基于医学证据的特异性推荐基础。
  • 原文结论指出,在制定出具体措施并转化为实际降低出血风险的策略之前,提供者将被迫在一条尚未明确建立的细红线上平衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coronary artery disease and acute coronary syndrome (ACS) are both common in patients with chronic kidney disease (CKD). CKD patients have higher risks of bleeding and thrombosis. However, they remain under-represented in major randomized clinical trials (RCTs), and there is no medical evidence-based foundation on which to issue specific recommendations about the management of ACS in CKD. CKD patients with ACS frequently are diagnosed later, receive fewer acute interventions and are at increased risk of over-dosage of medications and under-prescription/under-performance of interventional treatments than CKD patients without ACS. The lack of RCTs should not discourage reliance on clinical common sense, while clearer decisional algorithms with better outcomes are a priority for urgent development. Future guidelines should further refine the assessment of CKD with ACS while placing much greater emphasis on the correct dosing of medications based on contemporaneous renal function. Until a strategy is designed with specific measures translated into the actual decrease of bleeding risk, providers will be forced to balance the equilibrium on a thin red line that is not clearly established.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Burlacu A, Genovesi S, Ortiz A, et al. The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients. Nephrol Dial Transplant. 2017. PMID: 28371905. doi:10.1093/ndt/gfx041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。